Related Experiment Video
Updated: May 28, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Mechanical Thrombectomy in Patients with Malignancy: Comparable Procedural Success but Less Favorable Long-Term
Sena Aksoy1, Arsida Bajrami1, Songül Şenadım1
1Department of Neurology, Istanbul Aydın University Florya Medical Park Hospital, Istanbul 34295, Turkey.
Brain Sciences
|May 27, 2026
Summary
Mechanical thrombectomy (MT) is safe for acute ischemic stroke patients with cancer, but survival and functional outcomes are worse due to cancer, not the procedure itself. Careful patient selection is crucial.
Area of Science:
- Neurology
- Oncology
- Interventional Radiology
Background:
- Mechanical thrombectomy (MT) trials often exclude patients with malignancy.
- Evidence on MT safety and efficacy in cancer patients with acute ischemic stroke (AIS) is limited.
Purpose of the Study:
- Compare procedural success, functional outcomes, and mortality in AIS patients with and without malignancy undergoing MT.
Main Methods:
- Retrospective analysis of 110 AIS patients treated with MT.
- Stratification into malignancy (n=48) and no malignancy (n=62) groups.
- Comparison of baseline characteristics, procedural metrics, and clinical outcomes (functional independence, mortality, hemorrhage).
Main Results:
- Successful reperfusion (TICI 2b-3) rates were similar between groups (95.8% vs. 98.4%).
- Functional independence at 90 days was lower in the malignancy group (42.6% vs. 61.3%, p=0.04).
- 90-day mortality was significantly higher in the malignancy group (44.7% vs. 19.4%, p=0.004).
Conclusions:
- MT is technically effective and safe in AIS patients with malignancy.
- Poorer long-term functional recovery and survival in cancer patients are likely due to cancer, not MT.
- Careful patient selection and multidisciplinary decision-making are essential for this population.
